Tumor Targeting In Vivo Phage Library Screening Service

Background Tumor Targeting In Vivo Screening Platform FAQ Resources

Creative Biolabs offers custom phage display services to identify tumor targeting peptides by our innovative in vivo phage display technical platform. This exclusive platform can be used to analyze the structure and molecular diversity of tumor vasculature and to select tumor-specific antigens which have revealed stage- and type-specific markers of tumor blood vessels.

Background

Neoangiogenesis is very important for tumor development. Both blood and lymphatic vessels of tumor express unique markers that distinguish them from normal tissue vasculatures. According to the vascular heterogeneity and changed microenvironment, tumor vasculatures show multiple alterations and differences with regular tissue vasculatures, such as abnormal vessel wall structures, leakiness to macromolecules and constant formation and/or remodeling of vessels. Relevant studies have shown that the endothelial cells of tumor are involved in the variable expression of cell surface molecules by expressing a stimulated phenotype. In addition, the adhesive interaction between tumor cells and organ-specific endothelial markers is also essential for homing tumor cells. Through in vivo mapping of aggressive tumors, peptides homing to the tumor vessels may offer right opportunities to develop vehicles to transport cargo toxic agents to the tumor vasculature. In this way, in vivo phage display is the chosen technology to isolate and screen the novel targets of tumor cells and is able to build up a foundation of developing diagnostic targets and therapeutic agents against a variety of tumor types.

Tumor Targeting In Vivo Phage Library Screening Platform

Scientists of Creative Biolabs have developed an exclusive in vivo phage display platform for identifying specific markers of tumor vasculature. This platform can be extensively used to screen novel targets for tumor therapy through interrogating the surface of various cells. These peptides identified by in vivo phage display might be used as selective vehicles transporting chemotherapeutic agents to the tumor vasculature, thus improving drug specificity and efficacy and reducing toxicity. Furthermore, some peptides selected by in vivo phage display have been used to recognize and manage a large range of tumors, such as thyroid tumors, rat glioblastoma, prostate cancer, malignant melanoma and leukemia.

Creative Biolabs has established an effective phage display platform, supported by our exclusive in vivo phage display screening technology. Our comprehensive in vivo phage display services are competent to fit very unique research objectives from our global customers.

Fig.1 Selection of tumor-associated phage.¹

Other optional in vivo phage display screening services:

Reference

Veleva, Anka N., et al. "Efficient in vivo selection of a novel tumor-associated peptide from a phage display library." Molecules 16.1 (2011): 900-914. Distributed under Open Access license CC BY 3.0. The image was modified by revising the title.

FAQ

What is tumor-targeting in vivo phage display library screening?
Tumor-targeting in vivo phage display library screening is a technique that uses bacteriophage libraries to identify peptides, proteins, or antibodies that specifically bind to tumor cells or tumor-associated microenvironments. This method enables the discovery of ligands that can home to tumor tissues, facilitating the development of targeted cancer therapies and diagnostics.
Why is tumor-targeting important in cancer research?
Tumor-targeting is crucial for enhancing the specificity and efficacy of cancer treatments. By directing therapies specifically to tumor sites, researchers aim to increase drug concentration at the target site while minimizing exposure to healthy tissues, thereby reducing side effects and improving patient outcomes.
What are the primary applications of tumor-targeting phage display?
Applications include the development of targeted drug delivery systems that carry chemotherapeutic agents directly to tumor cells, the creation of more precise imaging agents for cancer diagnosis, and the identification of new biomarkers for early cancer detection and monitoring of treatment response.
What types of molecules are identified through tumor-targeting phage display?
Molecules identified typically include peptides or small proteins that can bind to specific receptors overexpressed on tumor cells or components of the tumor microenvironment, such as angiogenic blood vessels, extracellular matrix proteins, or immune modulatory signals within the tumor.
How does tumor-targeting phage display differ from other targeting methods?
Tumor-targeting phage display specifically adapts to the complexities of the tumor environment, including its heterogeneity, the presence of various cell types, and the dynamic nature of tumor progression. It also addresses challenges such as tumor penetration and the avoidance of immune system clearance.